rest in Biological Technology

Sarbanes-Oxley for the Rest of Us

Since the passage of the much-hailed (and cursed) Sarbanes-Oxley Act of 2002 (Sarbox), many publicly traded companies have restructured their boards, revised their financial recording and accounting practices and updated their codes of ethics. Many people have asked whether privately held companie...

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

... These clinical trials play a crucial role in evaluating potential therapeutic treatments for many critical health challenges facing the U.S. and the rest of the world. Since the Clinical Center's opening in 1953, more than 350,000 patients from all 50 states and around the world have participated in it...

Jatropha Couple Oil Crop Cultivation Technology Commercially Released

... The Director Plant Science CJP Mr. R.R. Sharma has stated that, "Jatropha plantation occupy about 50% of the planted land and to utilized the rest of land in sustainable manner we have been experimenting different intercropping options, patterns and agro- technologies. We have been in search of s...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

...ined an option to co-promote Intermezzo ((R) )to psychiatrists in the United States and has retained rights to commercialize Intermezzo ((R)) in the rest of the world. Under the terms of the agreement, Purdue will pay Transcept near-term milestones that include an upfront cash payment of $25 mill...

Bacteria pack their own demise

...e and function of the toxin-antitoxin complex, a system that had not been the focus of much interest in the past. Only in the last couple of years the rest of the scientific world come to realize its importance and as a result the number of papers in this field has exploded. All living creatures, people ...

Sanofi-aventis Announces Second Quarter 2009 Results

... were down 27.4% at euro 108 million. This decrease was due to extensive catch-up campaigns in the prior year. Excluding Gardasil ((R)) , sales of the rest of the portfolio were stable. First-half sales at Sanofi Pasteur MSD were down 11.8% on a reported basis at euro 487 million. Net sales ...

Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan

...e. Supplement applications command the major market share with over 87 percent of PUFA being used in dietary supplements whereas F&B comprises the rest 13 percent. In food, probiotics have for long been used in the global market; this is a moderately new concept in India. Commonly dairy foods h...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...parate comprehensive analytics for US, Europe, and rest of World. Annual forecasts are provided for each r...y Geographic Region/ Country - US, Europe, and rest of World Markets Independently Analyzed with A... Breakdown of Dollar Sales for US, Europe, and rest of World Markets for Years 2006, 2009 & 20...

New Report Just Published: World Endoscopy Systems Market Report

...a, Japan, Europe, Asia-Pacific, Latin America, and rest of World. Annual forecasts are provided for each r...a-Pacific (excluding Japan), Latin America and rest of World Markets Independently Analyzed with A...a-Pacific (excluding Japan), Latin America and rest of World Markets for Years 2000, 2009 and 2015...

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

...the Angels' game, Corey will again enter onto the field with other ALS patients to repeat a similar ceremony in the Angels' stadium and then spend the rest of the day with other ALS patients and advocates attending the game as well. More information on Corey and his efforts can be found online at ...

EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements

... data behind it. We are pleased with the EFSA's safety assessment of chromium picolinate. The standards set by the EFSA are the gold standards for the rest of the world and we believe this bodes well for Nutrition 21." Chromax chromium picolinate is Nutrition 21's top selling nutritional supplement i...

Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

...s, Anti-Epileptics, Autoimmune Agents, and Others. Major regional markets analyzed in the report include USA, Canada, Japan, Europe, Asia-Pacific, and rest of World. Analytics for the period 2006-2015 provide a comprehensive understanding of the market. Additionally, historic review is provided for the pe...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...harm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months. The license agreement includes royalties on net sales to Access. "SpePharm and Access are pleased with...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

...nd potential partners, and we look forward to reporting on progress and additional results from all three of our Phase II bavituximab studies over the rest of the year." About Phosphatidylserine (PS)-Targeting Therapies The rapid and disorganized growth that is the hallmark of cancer results in ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

...ion in the marketed EGFR drugs. The trial data demonstrate that patients have the prospect of equivalent clinical benefit from nimotuzumab as from the rest of the class without the physical, emotional and financial costs that result from the numerous and severe toxicities of Erbitux(R) which are a consequ...

Regular light bulbs made super-efficient with ultra-fast laser

...e glass of the bulb and altered a small area on the filament. When we lit the bulb, we could actually see this one patch was clearly brighter than the rest of the filament, but there was no change in the bulb's energy usage." The key to creating the super-filament is an ultra-brief, ultra-intense beam o...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...ent, has exclusive rights to market the medication as CAELYX throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL...or Ortho Biotech Products, L.P. has marketing rights for the product in the rest of the world. About Centocor Ortho Biotech Products, L.P. Cen...

Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009

...equn Huang, Company President and CEO. "We expect that increased marketing efforts and expanded distribution will help boost additional growth for the rest of 2009, with projected improvements in both margins and profitability." About Sinobiopharma Sinobiopharma, Inc. is a fully integrated and...

The Hamner Institutes Announce Partnership With China Medical City

...education, the Institute will help to produce new biomedical technologies that benefit the United States and People's Republic of China as well as the rest of the world. During the first phase of this agreement, the Institute for International Drug Development will be established at The Hamner's cam...

China Biologic Products Announces Strong First Quarter 2009 Results

...crease due to the foreign exchange translation. During the first quarter of 2009, Dalin contributed to approximately $9.5 million in revenue, and the rest of revenue was generated from Shandong Taibang, which experienced a 49.3% increase from the first quarter of 2008 to approximately $11.6 million. All ...

Spectral announces first quarter 2009 results

...,000 as at December 31, 2008. Management expects that the Company will maintain a minimum cash and short term investment balance of $3,000,000 for the rest of 2009. About Spectral Diagnostics Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Ass...

New Danish research shows how oil gets stuck underground

...es" in tiny pores and gaps and only some of the oil can be pressed out of the chalk and into the borehole by injecting water into the chalk layer. The rest is left behind as small droplets of oil surrounded by water either in small gaps in the rock or stuck to the walls of the pores. The chalk particles o...

deCODE genetics Announces First Quarter 2009 Financial Results

...of our major genetic risk markers also underscores the wisdom of our approach to intellectual property, both for differentiating our products from the rest of the field and for pursuing additional licensing partnerships. At the same time, we are engaged in negotiations on large-scale sequencing collaborat...

Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma

...HP System(TM) is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while minimizing entry of the drugs into the rest of the patient's circulation. This isolation limits toxicities which result from systemic chemotherapy treatments. Patients in the Phase III tria...

Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA

...authority on research in the small-cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them. We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas . BeaconE...

Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award

...aspects of our work is succeeding. I would like to express my gratitude to our outstanding teams, who have made this possible. Our sponsors can also rest assured that we will continue to focus on excellence in our operations." Dr. Kai E. Lindevall, Executive Chairman of Encorium Group, stated, "It ...

The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health

...rter of 2009 came to a close were forced to announce layoffs, and the U.S. economic crisis impacted a field once thought immune to the troubles of the rest of the country as job creation for March contracted by 50 percent. Seattle, WA (PRWEB) March 23, 2009 -- As the first quart...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

...untries of Europe. In October 2008, MuGard was granted CE Mark certification by the Dutch Notified Body (KEMA). SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months. Access will receive significant royalties on net sales. "SpePharm and Access are pleased with the comm...

Self-assembled nanowires could make chips smaller and faster

... nanowire channel used in the researchers' demonstration transistor was grown by metal organic chemical vapor deposition using gold as a catalyst. The rest of the transistor was made with conventional microfabrication techniques. While the diameter of the transistor's nanowire channel was approximately ...

Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer

...ncy of these events. As Mpex has retained global rights to MP-376 and the conclusion of the Phase II trials nears, I look forward to working with the rest of the management team to help Mpex achieve full potential for this new product opportunity." About Mpex Pharmaceuticals Mpex Pharmaceutical...

Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board

...velopment of linezolid, the sole marketed antibiotic in the oxazolidinone class. "I look forward to working closely with Dr. Prokocimer and the rest of the Trius team to help develop the clinical and regulatory strategy for torezolid as it moves into Phase 3 testing," said Dr. Corey. "The gu...

Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries

... Johnson & Johnson LLC will have exclusive rights to distribute Simbionix's line of advanced medical simulators in hospitals in Russia and the rest of the CIS. "We are very excited to enter into this collaboration with Johnson & Johnson LLC to bring our advanced simulators into Russian ...

Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza

...in Japan in March 2010 and get approval within 2010, while Daiichi Sankyo and Biota are seeking licensees for the drug product collaboratively for the rest of world market. Hovione retains the right to commercialize TwinCaps(R) outside the field of influenza. Peter Villax, Hovione's Vice President ...

Beacon Equity Issues Trade Alerts on Market Movers: CAH, LEAP, FISV, PBG, ARNA, LEN

...authority on research in the small-cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them. We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas . BeaconE...

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)

... INSMED WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S. IDIS WILL HAVE RESPONSIBILITY FOR rest OF WORLD RICHMOND, Va., March 30 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical company, today announced the si...

Hoosiers Work for Health Highlights Impact of Medical Research and Innovation on Indiana Economy

...antial contribution to U.S. economic growth, and that on average, this sector contributed more to GDP on a per employee basis and grew faster than the rest of the economy from 1996 to 2006." In addition, the local presence of the biopharmaceutical industry has a job multiplier effect, supporting an...

FasterCures Rewards Two InnoCentive Solvers for Innovative Ideas to Accelerate Medical Research

...enefits. As a result, companies often patent the biomarkers they discover and utilize them in their own research, which can limit their benefit to the rest of the research community, despite the fact that biomarkers frequently have a very broad range of potential clinical and non-clinical applications. ...

Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry

...40 percent came from North America, 24 percent from Western Europe, 22 percent from Asia-Pacific, 7 percent from Eastern Europe and 7 percent from the rest of the world. Participants represented different sectors within the life sciences industry, including healthcare services (23 percent), pharmaceutical...

China Bio-Immunity Corporation - Rabies Vaccine Recall

...atory rules. Among 360,200 doses of the flawed rabies vaccines in China, a total of 323,200 have been recovered by the manufacturer, Dalian JGAD. The rest of the rabies vaccines were not used and had been held for recall. To date, there has been no report of vaccine related illness received by Chinese Na...

NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results

...vestment. We also took approximately $415,000 of incremental bad debt expense in Q4 08 over and above what we took in Q3 08 in order to write off the rest of the accounts receivable balance left in our previous billing system, which was replaced in March 2008, and provide for a more adequate reserve bala...